Nuevocor, a preclinical-stage biotech company specializing in gene therapy for cardiomyopathies, has announced the completion of an oversubscribed $24 million Series A financing round.
Carmine Therapeutics, Inc., an emerging leader in gene therapy, announced that Don Haut, PhD has been appointed as its Chief Executive Officer, and member of the Board of Directors.